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Summary The potent mitogenic activity of insulin-like growth factor (IGF-I) on breast epithelium is inhibited by retinoic acid in oestrogen
receptor-positive (ER+) breast cancer cell lines. We studied and compared the effects of N-(4-hydroxyphenyl)-retinamide (4-HPR) in terms of
growth inhibition and modulation of the IGF-I system in ER+ (MCF-7) and oestrogen receptor-negative (ER-) (MDA-MB231) breast cancer
cell lines. Treatment with 1-10 gm 4-HPR for up to 96 h induced a dose- and time-dependent inhibition of proliferation in both breast cancer
cell lines. Induction of apoptosis was much more evident in MCF-7 than in MDA-MB231 cells (30-40% compared with 0-5% respectively
at 5 gM for 48 h). Exogenous human recombinant IGF-I (hr-IGF-I)-stimulated cell proliferation was abolished by 1 ,UM 4-HPR in MCF-7 cells.
'mmunoreactive IGF-I-like protein concentration in conditioned medium was reduced by 38% in MCF-7 and by 90% in MDA-MB231 cell lines
following treatment for 48 h with 5 gM 4-HPR. Western ligand blot analysis showed a reduction of IGF-binding protein 4 (BP4) and BP5 by
67% and 87%, respectively, in MCF-7, whereas IGF-BP4 and -BP1 were reduced by approximately 20% in MDA-MB231 cells. Exposure to 5
gM 4-HPR for 48 h inhibited [1251]IGF-I binding and Scatchard analysis revealed a decrease of more than 50% in maximum binding capacity
(Bmax) and a reduced receptor number/cell in both cancer cell lines. Steady-state type IGF-receptor mRNA levels were reduced by
approximately 30% in both tumour cell lines. We conclude that 4-HPR induces a significant down-regulation of the IGF-I system in both ER+
(MCF-7) and ER- (MDA-MB231) breast cancer cell lines. These findings suggest that, in our model, interference with the ER signalling
pathway is not the only mechanism of breast cancer growth inhibition by 4-HPR.
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The family of insulin-like growth factor (IGF) structurally related
ligands, their receptors and their binding proteins, plays a pivotal
role in cell growth through several mechanisms: (1) it is highly
mitogenic; (2) it protects cells from apoptosis; and (3) it is
required for the establishment and maintenance ofthe transformed
phenotype and for tumorigenesis (Baserga, 1995). IGFs are bound
to a family of binding proteins (IGF-BP) that are responsible for
protecting circulating IGFs, prolonging their half-lives and deliv-
ering them to their specific target tissues. At the local level, IGF-
BPs regulate the interaction of IGFs with their receptors and may,
in addition, have some independent actions (LeRoith et al, 1992,
1995). There is extensive evidence that the IGF-I system is impor-
tant in breast carcinogenesis (Bruning et al, 1992; Stoll, 1993;
Kazer, 1995). In vitro, IGF-I is the most potent mitogen for breast
cancer cell lines, where it mediates some oestrogen actions (van
der Burg et al, 1990). Retinoids, the natural and synthetic
analogues of vitamin A, exert profound effects on several physio-
logical functions, including control ofproliferation, differentiation
and homeostasis (Evans, 1988). Their effects are mainly mediated
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by two classes of nuclear receptors, the retinoic acid receptors
(RAR) and the retinoid X receptors (RXR), which are members of
the steroid-thyroid hormone receptor superfamily (Leid et al,
1992). Ample evidence exists showing that retinoic acid (RA) is a
potent inhibitor ofoestrogen receptor-positive (ER+) breast cancer
cell growth (Lotan, 1979; Lacroix and Lippman, 1980). Several
studies have recently demonstrated that the antiproliferative effect
ofRA in breast cancer cells is significantly influenced by the inhi-
bition of IGF-I-stimulated growth (Fontana et al, 1991; Adamo et
al, 1992). The growth-inhibitory response to the natural retinoids
(RA and 9-cis-RA) is correlated with ER expression (Roman et al,
1992; van der Burg et al, 1993) and, with the down-regulation of
target genes in the ER pathway (e.g. progesterone receptor and
pS2), indicates that retinoids exert their inhibitory effects in part
through interference with the oestrogen signal transduction
pathway downstream of ER (Roman et al, 1992; Rubin et al,
1994). Moreover, oestradiol enhances RARoc expression in several
ER+ breast cancer cell lines, which in turn results in increased
sensitivity to the growth-inhibitory effects of RA (Rishi et al,
1995). Interestingly, this cell growth inhibition is much more
evident in ER+ cells as RARox at high concentrations can dimerize
with c-Jun proto-oncogene, thus preventing its binding to AP-1
site (Schule et al, 1991). This may, in turn, interfere with the
activity ofIGF-I on c-Fos mRNA, thus resulting in an inhibition of
mitogenesis (Li et al, 1994). N-(4-hydroxyphenyl)-retinamide (4-
HPR), or fenretinide, is a synthetic analogue ofRA which inhibits
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breast cancer cell growth (Marth et al, 1985) and has potent
preventive effects in rodent mammary tumour models (Moon et al,
1979). Based on its good toxicity profile, this retinoid is currently
being tested in a large breast cancer prevention trial (Costa et al,
1994). One characteristic feature of 4-HPR is its selective ability
to induce apoptosis in a variety of cell lines, including RA-resis-
tant clones (Lotan, 1995; Ponzoni et al, 1995). These observations
have supported the contention that at least part of the activity of
the retinoid is not mediated by binding to RARs (Delia et al, 1995;
Sheikh et al, 1995). However, recent data have shown that 4-HPR
maintains the inhibitory activity of RA on the AP-1-regulated
proliferative signal but has a reduced ability to transactivate with
RARs (Fanjul et al, 1996). Although these properties may imply a
limited spectrum of activity, they should nonetheless confer a
reduced toxicity, which is known to be a major limiting factor for
natural retinoids (Smith et al, 1992). Within an ongoing secondary
prevention trial, we observed that 4-HPR lowers plasma IGF-I
concentrations, particularly in premenopausal women (Torrisi et
al, 1993). Since IGF-I activity in peripheral target tissues is
affected by its circulating levels (LeRoith et al, 1992), the fenre-
tinide-induced inhibitory effect may be an important mechanism
for breast cancer prevention (Decensi et al, 1997). To gain further
insight into this clinical observation, we studied the effect of 4-
HPR on the IGF-I system in two different breast cancer cell lines
and its association with growth inhibition.
MATERIALS AND METHODS
Materials
4-HPR was kindly provided by RW Johnson Pharmaceutical
Research Institute, Spring House, PA, USA. A stock solution,
which was aliquoted and stored at -80°C in foil-wrapped vials, was
made by dissolving 4-HPR in absolute ethanol at a concentration of
0.391 mg ml-' (1 mM). In order to avoid photoisomerization, all
procedures involving 4-HPR were performed under subdued
lighting. Lyophilized pure (> 97%) human recombinant IGF-I (hr-
IGF-I), from Pepro Tech. (Rocky Hill, NJ, USA), was reconstituted
in 0.1 N acetic acid, aliquoted at 10 ,tg 100 1tl-'and stored at -20°C.
Lyophilized Des-(1-3)IGF-I, reconstituted in 10mM HCI,
aliquoted and stored as hr-IGF-I, was purchased from GroPep
(Adelaide, Australia). Lyophilized iodinated IGF-I (['12I]IGF-I)
(IM172, specific activity 2000 Ci mmol-', 74 TBq mmol-'), recon-
stituted in 0.1 N acetic acid, aliquoted at 2 ,uCi 20 tl-' and stored at
-20°C and [methyl-3H]-thymidine ([3H]dThd) (TRA 120, specific
activity 5 Ci mmol-', 185 GBq mmol-'), reconstituted in saline
solution, aliquoted at 160 ,uCi ml-' and stored at 4°C were
purchased from Amersham International (UK). 3-[4,5-dimethylthi-
azol-2yl]-2,5-diphenyl tetrazolium bromide (MTT), phenylmethyl-
sulphonyl fluoride, leupeptin, pepstatin-A as well as bovine serum
albumin (BSA; RIA grade) were from Sigma. The anti-IGF-I rabbit
polyclonal antibody (UBK 478) was kindly donated by the
National Hormone and Pituitary Program distributed by the
Hormone Distribution Program of the NIDDKD, National Institute
of Health (Bethesda, MD, USA). Anti-IGF-BP polyclonal anti-
bodies were from Upstate Biotechnology, Lake Placid, NY, USA.
Rabbit IgG HRP-conjugate was purchased from Dako, Milan, Italy.
Cell lines and culture conditions
MCF-7, an oestrogen receptor-positive and oestrogen-dependent
human breast cancer cell line, was provided by G Leclercq
(Institute J. Bordet, Brussels, Belgium) whereas MDA-MB231, an
oestrogen receptor-negative human breast cancer cell line, as well
as the epithelium-like HBL-l00 line, derived from breast milk of
an apparently healthy 27-year-old woman (Polanowski et al,
1976), were obtained from M E Lippman (Georgetown University,
V. T. Lombardi Cancer Center, Washington DC, USA). Cells were
incubated in Dulbecco minimum essential medium (DMEM),
supplemented with 5% heat-inactivated fetal calf serum, 2 mM
glutamine, antibiotics and 1% non-essential amino acids.
Whenever required, cells were grown either in phenol red-free
DMEM supplemented with 5% heat-inactivated, dextran char-
coal-steroid depleted fetal calf serum (FCS) or in serum-free
medium (SFM).
Conditioned medium
Subconfluent cell monolayers were washed, SFM was added and
the whole incubated as usual. After 24 h SFM was replaced with
fresh S gM 4-HPR-containing or drug-free SFM for 48 additional
hours of culture. Conditioned medium (CM) was harvested,
protease inhibitors were added and an aliquot from each experi-
mental condition was concentrated (30-fold) in a Centricon-3
microconcentrator (Amicon, Beverly, MA, USA). Total protein
content in the concentrated CM from retinoid-treated and
-untreated cells was then determined by Bradford assay. The
values were used to normalize the amounts of each sample used
for the electrophoretic separation.
Cell growth response to the retinoid
The concentration and time response effects of continuous expo-
sure to 4-HPR, ranging from 1 to 10 tM, on cell proliferation and
DNA synthesis were studied by MTT and [3H]dThd incorporation
assays respectively. Cells were plated (3-6 x 103 cells per 96-well
multiwell) in quadruplicate and 4-HPR was added 24 h later. The
MTT assay was performed, as described in previous work (de
Cupis et al, 1995), after 48, 72 and 96 h of treatment. In order to
define whether exposure to 4-HPR for 48 h had a cytotoxic or
cytostatic activity, the reversibility of its antiproliferative effect
was assessed by time course MTT experiments. Specifically, cells
were plated (3-6 x 103 per 96-well multiwell) in quadruplicate and
treated with increasing concentrations of 4-HPR. After 48 h,
medium was removed and cells were cultured for 48 and 72 addi-
tional hours in drug-free medium.
Estimation of DNA synthesis after 24 h continuous exposure to
4-HPR, alone or in combination with 10 nM IGF-I, was performed
following the procedures described in a previous report (Favoni et
al, 1994). In brief, cells were plated in triplicate (7.5 x 104 ml-') in
35-mm-diameter Petri dishes. After overnight incubation, cells
were treated for 24 h with IGF-I and/or 4-HPR in SFM. Briefly,
2 tCi ml-' labelled thymidine was added to each well 2 h before
the end of treatment. After washing, monolayers were solubilized
and radioactivity was detected in a 3-counter.
DNA analysis by flow cytometry
The cells were harvested and fixed in cold 70% ethanol for at least
24 h. After extensive washing with phosphate-buffered saline
(PBS), the samples were incubated for 30 min at room temperature
with the DNA staining solution containing 30 ,tg ml' propidium
iodide and 0.5 Ltg ml-' of RNAase and measured on an Epics Elite
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flow cytometer (Coulter Electronics, Hialeah, FL, USA). The
DNA histograms were analysed, by the multicycle program
(Phoenix Flow Systems, San Diego, CA, USA), for the evaluation
ofapoptosis and the percentage ofcells in the various phases ofthe
cell cycle (Darzynkiewicz et al, 1992). To clarify the kinetics of
cell transition through the S and the G, + M phases of the cell
cycle, a simple stathmokinetic (or 'mitotic arrest') experiment
(Traganos and Kimmel, 1990) was performed. Before harvesting,
the cells were treated with 0.1 ig ml-' of the mitotic blocker
colcemid (Gibco, Grand Island, NY, USA) for 8 h. In this way, all
those cells which are in late S phase and in G2 phase are arrested in
M phase at the time of harvesting. The comparison of the
colcemid-induced increase in the GI + M peaks of exponentially
growing untreated and 4-HPR-treated cultures, may reveal pertur-
bations in cell progression through S and G, cell cycle phases.
IGF-l/BP complex separation and radioimmunoassay
Aliquots of concentrated CM from treated (5 gM 4-HPR for 48 h)
and untreated cells were analysed to determine the concentration
of IGF-I-like material using a specific radioimmunoassay (RIA),
as previously described (Favoni et al, 1995). As IGF-BPs may
interfere in a standard RIA, producing false results, a RIA buffer
containing heparin, which allows IGF-I/IGF-BP dissociation, was
used (Favoni et al, 1995). In addition, a separate assay for binding
proteins was performed to ensure complete BP removal: heparin-
treated samples were dried and resuspended in 0.1I% BSA-PBS
containing 30 000 counts per minute of radiolabelled IGF-I and
incubated overnight at 4°C. After incubation for 30 min on ice and
centrifugation, unbound labelled IGF-I was precipitated with
0.5 ml of ice-cold activated charcoal (5% w/v suspension in 2%
BSA-PBS). Labelled IGF-I which was complexed to binding
proteins present in the sample and remained in the supernatant was
counted on a Beckman 5500B y-counter.
Electrophoresis and Western ligand analysis
Appropriate volumes of concentrated CM were resolved by
sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) and blotted on nitrocellulose to quali-quantitatively
characterize IGF-BPs, using the procedures previously described
(Favoni et al, 1994). Binding proteins were visualized by auto-
radiography and their molecular weight estimated by comparison
to defined low-range (18 000-106 000 Mr) prestained molecular
weight markers (Bio-Rad Laboratories, Richmond, CA, USA).
Specific pure human recombinant IGF-binding proteins (hr-IGF-
BP4, hr-IGF-BP2, hr-IGF-BP5 from Austral Biologicals, San
Ramon, CA, USA; hr-IGF-BP3 from UBI, Lake Placid, NY, USA
and hr-IGF-BPl from Dr GN Cox, Synergen, Boulder, CO, USA)
were run as well; their quantities and the degree of variation were
calculated by a densitometric analysis ofthe autoradiography with
a LKB Ultroscan XL laser densitometer (Pharmacia/LKB,
Uppsala, Sweden).
Binding experiments
Binding of IGF-I to its specific cell-surface type I IGF receptor
(IGF-R) and its modulation by 4-HPR was studied by radioreceptor
assay, using the procedure previously described (de Cupis et al,
1995). Briefly, cells were plated in duplicate in 24-well plates
at a density of 100000 to 200000 cells per well in 1 ml of
phenol red-free DMEM supplemented with 5% dextran
charcoal-steroid depleted FCS in the presence or absence of5 gM 4-
HPR and incubated under standard conditions. After 48 h, the
medium was replaced by binding buffer for one additional hour at
37°C. Competition was carried out by adding 30 000 counts per
minute of ['251]IGF-I to each well along with increasing concentra-
tions (0.195-400 ng ml-') ofcompeting ligand. At the completion of
the binding period (2 h at 4°C with gentle shaking), cells were
washed three times with ice-cold washing buffer (0.1%
BSA-Hanks' balanced salt solution), after which the monolayers
were harvested in lysing buffer. Bound IGF-I was determined on a
Beckman 5500B y-counter and the specific binding was expressed
as the percentage of bound IGF-I in the absence of competing
peptide. Scatchard analysis was performed to determine the dissoci-
ation constant (Kd) and the maximum binding capacity (Bmax) rela-
tive to 4-HPR-treated and untreated cells. According to some
experimental studies (Hsu and Oleksky, 1992; Heding et al, 1996),
which report that native IGF-I can also bind to cell surface-associ-
ated BPs, a group of assays with Des-(1-3)IGF-I was carried out to
obtain a convincing interpretation of the competitive binding data.
Des-(1-3)IGF-I is an IGF-I derivative, with glycine, proline and
glutamic residues cleaved from the N-terminus, which binds mainly
to cell-surface receptors and poorly to the IGF-BPs. In radioreceptor
assays, following the same experimental procedure described above,
increasing concentrations ofDes-(1-3)IGF-I (0.195-400 ng ml-') as
the competing ligand rather than IGF-I were used.
RNA isolation and ribonuclease protection assay
RNA was isolated from cells using the method of Chirgwin et al
(1979), and integrity of the total cellular RNA was measured by
formaldehyde gel electrophoresis. Ribonuclease (RNAase) protec-
tion assay was performed as previously described (Yee et al,
1988). Briefly, 20 tl of total RNA from untreated and 48-h 4-
HPR-treated cells (5 gM) was hybridized with radiolabelled probes
overnight at 50°C. After ribonuclease A digestion, protected frag-
ments were visualized by denaturing polyacrylamide gel electro-
phoresis. Probes used in this study were transcribed from a 293-bp
Aval-Aval fragment of the IGF-R (Yee et al, 1989, 1992). A probe
transcribed from the 36B4 cDNA was used as a loading control.
36B4 encodes for a ribosomal protein that is not regulated by
hormones in breast cancer cells (Laborda, 1991). The RNA
samples were hybridized simultaneously with both probes.
pBR322 digested with MspI were end labelled and used as size
markers. The protected fragments were quantified using an Ambis
radioanalytical scanner. To determine the levels of type I IGF-
receptor mRNA, the net counts for the receptor protected fragment
were divided by the net counts for the 36B4 mRNA species.
Statistical analysis
Statistical significance of the experimental results, reported as a
mean percentage ± standard error, was evaluated by the non-
parametric Wilcoxon test.
RESULTS
Inhibition of growth by 4-HPR
The influence of increasing concentrations of4-HPR and duration
of4-HPR exposure on breast cancer cell growth is shown in Figure
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Figure 2 Cell growth recovery evaluated by MTT colorimetric assay after
48 h of drug treatment (Ol) followed by 48 h (A) and 72 h (B) of culture in
drug-free medium (U). Columns represent the mean ± SE of three
independent experiments: (1) untreated cells (LN); (2) 1 gM 4-HPR; (3)1 gM
4-HPR + fresh medium; (4) 1.5 [M 4-HPR; (5) 1.5 gM 4-HPR + fresh medium;
(6) 2.5 gM 4-HPR; (7) 2.5 lM 4-HPR + fresh medium; (8) 5 gM 4-HPR;
(9) 5 gM 4-HPR + fresh medium; (10) 10 gM 4-HPR; (11) 10 gM 4-HPR +
fresh medium. Significant effect: 0.005 < P < 0.01 (no symbol on the top of
the column); OP = 0.006; *not significant
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Figure 1 Time- and dose-response effects of 4-HPR on proliferation of
human breast cancer cells MCF-7 (ER+) and MDA-MB231 (ER-) and the
pseudo-normal cell line HBL-100. Points, expressed as a percentage of
control, represent the absorbance measured at 540 nm and are the mean of
three independent experiments performed in quadruplicate. Standard error
ranged from 1 to 6%. 0, 48 h; 0, 72 h; O, 96 h. All the results are significant
(0.005 < P < 0.009; P = 0.034 only for MCF-7 1 gM 4-HPR at 48 h) except for
1 gM 4-HPR at 48 h for MDA-MB231 and for 1-5 gM 4-HPR at 48, 72 and
96 h for HBL-100
1. Growth curves of MTT experiments showed that both MCF-7
and MDA-MB231 breast cancer cell lines are sensitive to 4-HPR
in a time- and concentration-dependent manner: the pattern of
growth inhibition of the two cell lines was similar (Figure 1).
Specifically, cell proliferation was not affected at the dose of 1 gM
4-HPR except for MDA-MB231 at 96 h, whereas it was dramati-
cally inhibited at one log higher concentration. Overall, MCF-7
cells appeared more sensitive to short-term exposure to 4-HPR,
whereas MDA-MB231 cells seemed to be most sensitive after a
longer exposure. In contrast, the pseudo-normal HBL-100 breast-
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Table 1 Cell cycle distribution of MCF-7, MDA-MB231 and HBL-100 cell lines untreated and treated with 5 gM 4-HPR for 24, 48 and 72 h, stained with
propidium iodide and measured by flow cytometry (means ± SE)
Cell line
MCF-7 MDA-MB231 HBL-100
G (%) S G2 + M G2 + Ma Aptoptotic G,(%) S G2+ M G2 + Ma Aptoptotic GI(%) S G2 + M G2 + Ma Aptoptotic
cells (%) cells (%) cells (%)
Untreated 50+4 38+5 12+2 21 +3 0 49±2 38+1 13±1 36+4 0 53+4 30±4 13+3 31 ±5 0
4-HPR treated
24h 67+2 25±2 8+ 1 16+3 0 54±4 32±2 14±2 38+4 0 59+5 26±5 15±2 26+2 0
48h 74±5 13+3 13±2 16±4 30-40 63 10 27+ 11 10±1 16±7 0-5 73±4 19+4 8+1 14+1 0
72h 74±1 16+2 10+2 9+2 60-80 66±1 25+3 9±2 9+2 20-30 69±1 23±1 8±1 11 ±1 0
aCells exposed to 0.1,g ml-' colcemid for 8 h before harvesting.
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Figure 3 DNA content distribution in (A) untreated MCF-7 cells and MCF-7 cells treated with 5 IM 4-HPR for (B) 48 h or (C) 72 h. Histograms are
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Figure 4 Inhibition of exogenous IGF-I-stimulated cell proliferation induced
by simultaneous 4-HPR treatment for 24 h on MCF-7 cell line. Bars,
expressed as a percentage of control, represent the [3H]dThd incorporated
into DNA. Standard error ranged from 6 to 10%. Values, representing the
mean of four independent experiments performed in triplicate, are significant
(P< 0.001). M, Control; [, IGF-I 10 nM; O, 4-HPR 1 gM; 1, 4-HPR 5gM; mI,
IGF-I + 4-HPR 1,M; P9, IGF-I + 4-HPR 5gM
derived cell line was unaffected at doses below 5 gM (Figure 1).
Similar results were obtained with thymidine incorporation exper-
iments, in which 4-HPR (range 1-10 gM) induced a significant
progressive inhibition of [3H]dThd uptake (26-99%), with an IC90
of approximately 2.5 ,UM and 100% growth arrest within 24 h.
Again, the inhibitory activity of 4-HPR on HBL-100 was less
evident both at the lowest and the highest retinoid concentrations
(data not shown).
To establish whether the antiproliferative effect of 4-HPR (1-
10 ,UM 4-HPR for 48 h) was reversible upon its removal, MTT
experiments of cell growth recovery were performed. Upon drug
withdrawal, MCF-7 and MDA-MB231 cell lines again acquired
proliferative activity by 48 and 72 h in a 4-HPR-free culture
medium at all concentrations except for 10gM (recovery range
4-74% and 4-35% compared with 4-HPR-treated cells for MCF-7
and MDA-MB231 respectively), indicating that part of the
inhibitory effect of4-HPR was cytostatic rather than cytotoxic. As
expected, growth recovery of both cancer cell lines tended to
decrease with increasing 4-HPR concentrations (Figure 2).
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Figure 5 Effect of 5 IM 4-HPR on the secretion of immunoreactive IGF-I-like
material into the CM from MCF-7, MDA-MB231 and HBL-100 cell lines. Data
are reported as the means + SE of four independent experiments performed
in duplicate. Control; *, 4-HPR-treated. Statistical significance: P= 0.006,
except for HBL-100
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Figure 6 (A) Ligand blot of CM obtained from MCF-7 and MDA-MB231
human cells in the absence or presence of 5 pM 4-HPR. Molecular weight
standard is represented on the left axis, the molecular weight of IGF-BPs is
indicated on the right axis. Lanes: 1, MCF-7 untreated; 2, MCF-7 4-HPR-
treated; 3, MDA-MB231 untreated; 4, MDA-MB231 4-HPR-treated; A, hr-IGF-
BP4; B, hr-IGF-BP1; C, hr-IGF-BP5; D, hr-IGF-BP2; E, hr-IGF-BP3, 300 ng
per each IGF-BP were run. (B) Amounts of IGF-BP4, 1, 5 and 2 secreted by
MCF-7 and MDA-MB231 cell lines at the steady-state level (C]) and after 4-
HPR treatment (-). Columns represent the area (mm2) of each binding
protein, expressed in arbitrary units, obtained with densitometric analysis of
the autoradiography
DNA content analysis
Appearance of fractional DNA content, typical of apoptotic cells
(Darzynkiewicz et al, 1992), was found in 30-40% and in 60-80%
of MCF-7 cells following 48 and 72 h ofexposure to 5 ,UM 4-HPR
respectively (Table 1 and Figure 3). Moreover, an accumulation of
MCF-7 cells in the G, phase was already detectable at 24 h (Table
1). The 'mitotic arrest' assay showed that after 24 h 4-HPR expo-
sure, the colcemid-induced increase in the GI + M percentage was
similar to that observed in the untreated cells. In contrast, in cells
exposed for 48 and 72 h to 4-HPR, treatment with colcemid did
not modify the G, + M percentage, indicating that cell progression
through S- and G, phases was strongly curbed. In the ER- MDA-
MB231 cells, only a few apoptotic cells (0-5%) were evident at
48 h, rising to 20-30% after 72 h ofretinoid exposure. An increase
in the G, population was observed after 48 and 72 h, and progres-
sion through S- and G, phases was strongly delayed after 48 and
72 h treatment (Table 1). In contrast, no apoptotic cells were found
in 4-HPR-treated HBL-100 cells. There was a moderate increase
in the G, phase fraction, while progression through S- and G,
phases was not affected (Table 1).
Modulation of the IGF-I system by 4-HPR
To assess whether the inhibition of cell growth induced by 4-HPR
was directly mediated by down-regulation of the growth factor
mitogenic activity, exogenous hr-IGF-1-stimulated cell prolifera-
tion was measured by [3H]dThd incorporation assay during
concurrent administration of 1 or 5 tM 4-HPR. Exposure to 10 nM
hr-IGF-I induced cell growth stimulation only in MCF-7 cells
(68%) after 24 h (P < 0.001). This effect was abolished by 1 gM
and even counteracted by 5,M 4-HPR, reaching a 46% growth
inhibition from baseline (Figure 4).
The presence of immunoreactive IGF-I-like material in the CM
of all three cell lines was demonstrated by quadruplicate radio-
immunoassay experiments shown in Figure 5. As expected, higher
amounts ofsecreted polypeptide were found in ER- MDA-MB231
than in ER+ MCF-7 cell lines (in our experiment more than
sixfold). Treatment with 5 ,UM 4-HPR for 48 h induced a 38% and
90% reduction in the growth factor concentration in the CM from
MCF-7 and MDA-MB231 cells respectively. In contrast, the
synthetic retinoid had a marginal effect on the secretion of IGF-I-
like material in HBL-100 (Figure 5).
The presence of IGF-BP molecular species of 24 000, -32 000
and 34 000 Mr, corresponding to IGF-BP4, IGF-BP5 and IGF-
BP2, was detected under basal culture conditions in the CM from
MCF-7 cells (Figure 6A). The MDA-MB231 cell line also synthe-
sized and secreted IGF-BP4 together with IGF-BPl (30 000 Mr).
IGF-BP3, the largest 42-46 000 Mr IGF-BP, was also identified,
albeit very faintly, in MDA-MB231 cells, while it was not
expressed in MCF-7 cells (Figure 6A). Treatment with 4-HPR
induced a remarkable reduction in the amount of IGF-BP4 (by
67%) and IGF-BP5 (by 87%) and a 16% reduction in the amount
of IGF-BP2 secreted in the CM derived from MCF-7 cells (Figure
6B). In the CM collected from MDA-MB231, both IGF-BP4 and
IGF-BPI were decreased, by 24% and 20% respectively, while
IGF-BP3, which was very poorly expressed, appeared to be
reduced as well, although its levels were undetectable by densito-
metric analysis (Figure 6B). The analysis of CM from HBL-100
cells did not reveal any appreciable presence ofIGF-BPs (data not
shown).
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Figure 7 (A) Radioreceptor assays performed with either IGF-1 (@)and Des-(1-3)IGF-I (A) as competitor ligands, used at concentrations of 0.195-
400 ng ml-'. Data represent the means ± SE of three independent experiments performed in duplicate. (B) Scatchard analysis of competitive binding data using
two wells per point in three experiments. Bound/free ratios vs specific bound are indicated O, control; *, 4-HPR-treated. Insets: values of Kd (nM), Bmax (pM),
and number of high-affinity sites (x 104) per cell for untreated (control) and 4-HPR-treated cells
The ability of4-HPR to modify IGF-I binding to MCF-7, MDA-
MB231 and HBL-100 cell-surface IGF-R was assessed by
competitive binding assay and Scatchard analysis of the data.
Experiments carried out in the presence of either hr-IGF-I or its
truncated analogue Des-(1-3)IGF-I showed basically no differ-
ences in the polypeptides' binding ability because the same
amount (= 80%) of the total cell-associated ['251]-IGF-I was
displaced by both native and Des-(1-3)IGF-I in cell lines under
study (Figure 7A; HBL-100 data not shown). On the basis ofthese
results, subsequent radioreceptor assays were performed in accor-
dance with the standard procedure, only with the physiological
species of IGF-I. Both MCF-7 and MDA-MB231 cells had
approximately 90 000 sites per cell (Figure 7B, inset), whereas
HBL-100 had about 60000 sites per cell. The Kd was in the
nanomolar range for all three cell lines (data not shown). Scatchard
analysis revealed a linear plot, suggesting a typical (de Cupis et al,
1995; Hodgson et al, 1995) single binding site for IGF-I (Figure
7B). The maximal binding capacity was about 40pM for both
breast cancer cells and the pseudo-normal cell line. Forty-eight
hours' pretreatment with 5 ,UM 4-HPR did not significantly change
the binding affinity, but reduced the number of cell-surface recep-
tors in MCF-7 (by 30%) and MDA-MB231 (by 12%). In addition,
the Bmax values for MCF-7 and MDA-MB231 were reduced by
about 60% and 50% respectively (Figure 7B, inset). In contrast,
IGF-I receptor number, Kd and Bmax ofHBL-100 were only margin-
ally reduced by 4-HPR (data not shown).
Finally, treatment with 4-HPR at 5 gIM for 48 h induced a
decrease in steady-state levels of type I IGF-receptor mRNA by
30% and 37% ofcontrol in MCF-7 and MDA-MB231 cells respec-
tively (Figure 8).
DISCUSSION
Inhibition of the IGF-I system, the most potent mitogen for breast
cancer cells, is an important mechanism by which natural retinoids
antagonize in vitro breast cancer cell growth (Fontana et al, 1991;
Adamo et al, 1992; Roman et al, 1992; van der Burg et al, 1993;
Rubin et al, 1994). Consensus, moreover, points to the dependence
of these retinoids' growth-inhibitory effect on the expression of
the ER pathway (van der Burg et al, 1993; Roman et al, 1992;
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Figure 8 (A) RNAase protection analysis of IGF-R gene expression. Sizes
of IGF-R and 36B4 cDNA are marked on the right vertical axis. Lanes: 1,
markers; 2, probe transcribed from 36B4 cDNA; 3, MCF-7 USA as control; 4,
MCF-7 untreated; 5, MCF-7 4-HPR-treated; 6, MDA-MB231 untreated; 7,
MDA-MB231 4-HPR-treated. (B) Quantification of protected fragments
obtained by an Ambis radioanalytic scanner.C], Control;*, 4-HPR-treated
Rubin et al, 1994). Indeed, ER- breast cancer cells do not respond
to RA and 9-cis-RA, and IGF-R expression is not down-regulated
by these compounds in MDA-MB23 1 cells (Rubin et al, 1994). 4-
HPR is a well-tolerated synthetic retinoid which is currently being
evaluated by our group in a large prevention trial of second
primary breast cancer (Costa et al, 1994). Within the context ofthe
clinical study, we observed a significant inhibition of plasma IGF-
I levels in women receiving 4-HPR (Torrisi et al, 1993). To
provide further insight into this modulatory activity, we studied the
in vitro effect of 4-HPR on the IGF-I system and whether this
action was related to cell growth inhibition.
Our data indicate that 4-HPR can significantly inhibit the
growth ofboth ER+ MCF-7 and ER- MDA-MB23 1 breast cancer
cell lines. Although the pattern of growth inhibition varied
depending on the cell line in a time- and concentration-dependent
manner, the finding that the MDA-MB231 cell line was sensitive
to 4-HPR differs from what is commonly observed with RA and 9-
cis-RA (Roman et al, 1992; van der Burg et al, 1993; Rubin et al,
1994). It is, however, consistent with a recent observation by
Sheikh et al (1995), who showed that 1,tM 4-HPR was more
potent than RA, at the same concentration, as antiproliferative
agent on both MCF-7 and MDA-MB231 cell lines and that it
inhibited the growth of RA-resistant cells (Sheikh et al, 1995).
Although in our experiments cell lines appeared less sensitive to
that dose, the observed inhibition of ER- cells seemingly supports
the contention that at least part of the mechanism of 4-HPR
activity is not mediated by binding to retinoid receptors (Delia et
al, 1995; Lotan, 1995; Sheikh et al, 1995).
Cell exposure to the synthetic retinoid led to perturbations in
cell cycle progression in both neoplastic cell lines, as demon-
strated by flow cytometric studies. However, induction of
apoptosis was more rapid and extensive in MCF-7 than in MDA-
MB23 1 cells. Moreover, apoptosis was achieved at 5 tM or higher
doses, while below that threshold the growth-inhibitory effect was
reversible. Again, the preferential sensitivity to apoptosis in MCF-
7 in comparison with MDA-MB231 is consistent with the results
by Sheikh et al (1995), although these authors observed apoptosis
at 4-HPR doses as low as 1 ,UM. Thus, taken together, these data
suggest a link between the induction of apoptosis by the retinoid
and the ER pathway. In contrast to the data of Sheikh et al (1995),
Fanjul et al (1996) have recently shown that 4-HPR is a selective
ligand of retinoid receptors. In their experiments, 4-HPR was able
to transactivate moderately with RARy and, to a lesser extent, with
RAR,B in comparison with RA. More importantly, however, 4-
HPR was found to efficiently transrepress the AP- 1 complex with
RARa, induce apoptosis in different systems and, finally. overex-
press RARy. Although these effects could be detectable starting
from 5 gM, they were completely evident at 10-20 tM (Fanjul et
al, 1996). While this dose range exceeds the dose currently
employed in the clinic and is likely to be accompanied by an
excessive toxicity in humans, it is not known whether the
prolonged exposure to the drug in prevention trials might compen-
sate for this dose threshold effect. It is also unclear whether the
apparent discrepancies between these studies are traceable to the
presence of two distinct mechanistic pathways, one operating at
lower doses, independent of retinoid receptors, and the other
acting at higher doses through the binding to nuclear receptors.
Our results indicate that 4-HPR significantly inhibits the IGF-I
system and that this modulatory activity mediates the antiprolifer-
ative effect of the retinoid. In fact, concomitant administration of
4-HPR was able to counteract the proliferative stimulation induced
by exogenous IGF-I. As expected, ER- cells constitutionally
secrete higher concentrations of IGF-I-like material (Huff et al,
1986), and this partly explains the relative higher inhibition of its
secretion by 4-HPR in MDA-MB23 1 compared with MCF-7 cells.
Although breast cancer cells do not synthesize IGF-I mRNA (Yee
et al, 1989), a closely related peptide could be detected in all cell
lines using an anti-IGF-I polyclonal antibody. Moreover, binding
protein assays were performed after dissociation and separation of
the whole binding protein component, in order to exclude a
possible anti-IGF-I antibody/IGF-BPs cross-reactivity. Finally,
IGF-II RNAase protection assay showed no significant IGF-I1
mRNA expression in the cancer cell line examined (data not
shown). Taken together, these results indicate that the RIA quanti-
fied a molecule closely related to IGF-I.
Our experiments also show that 4-HPR was able to down-regu-
late IGF-I binding to IGF-R significantly in both tumour cell lines.
This down-regulation appears to be due to the inhibition of IGF-R
gene expression. These data are noteworthy, in as much as recent
studies have shown that neither RA nor 9-cis-RA down-regulate
the expression of type I IGF receptor in MDA-MB23 1 cells
(Rubin et al, 1994). Given the pivotal involvement of this receptor
in the control of proliferation, apoptosis and carcinogenesis
(Baserga, 1995), these effects are likely to be important in the
preventive activity of 4-HPR. Administration of 4-HPR caused a
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down-regulation in all IGF-BPs secreted by both cell lines, with
expected differences in secretion values between ER+ and ER-
cells (Figueroa and Yee, 1992). Since IGF-BP4, -BP5 and -BP2
have been shown to be positively involved in controlling cellular
proliferation (Figueroa and Yee, 1992), the retinoid-induced cell
growth inhibition may also be related to the observed decrease in
their secretion. Indeed, in a recent study, low IGF-BP4 was corre-
lated with improved survival in women with large tumour size
(Yee et al, 1994). Secretion ofIGF-BPl was evident only in MDA-
MB231, as previously described (Yee et al, 1991). Because the in
vitro biological effect of IGF-BPI tends to vary according to
experimental systems (Fugueroa and Yee, 1992; McGuire et al,
1992), its mild down-regulation by 4-HPR does not lend itself to
easy interpretation.
Consistent with most previous findings (Clemmons et al, 1990;
Figueroa et al, 1993), the presence ofIGF-BP3 was not identifiable
in MCF-7, whereas it was only slightly detectable in untreated
MDA-MB231 cells. There is also evidence that IGF-BP3 is under
the control of several ligands of the steroid superfamily. For
instance, its appearance in CM from MCF-7 and MDA-MB231 has
been documented after RA treatment (Adamo et al, 1992; Sheikh et
al, 1993; Gucev et al, 1996), and expression of gene and protein is
enhanced by anti-oestrogen and decreased by oestrogen adminis-
tration (Huynh et al, 1996). In our hands, exposure to 4-HPR was
associated with undetectable secretion in MCF-7 and with a
minimal decrease in IGF-BP3 in MDA-MB231. Differences in
techniques, in the compounds used and the heterogeneity of cell
cultures may account for these discrepancies. Indeed, we have
previously reported on the low detectability ofIGF-BP3 in the CM
from MDA-MB231 cells (de Cupis et al, 1995).
In conclusion, our results indicate that 4-HPR inhibits the
growth of both MCF-7 and MDA-MB231 human breast cancer
cell lines. These effects are associated and, at least in part, medi-
ated by a significant down-regulation of the IGF-I system and are
likely to characterize the clinical preventive potential of this
retinoid. Another study, extended to a wider panel of ER+ and
ER- breast cancer cell lines, is being planned in order to obtain
further evidence which will allow extrapolation of these prelimi-
nary findings to all breast cancers and lines.
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